Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin. (PubMed, Cancer Med) - Sep 3, 2026 - "Univariable logistic regression analyses showed that an eosinophil proportion of ≥ 2.5% was a risk factor for AE development (odds ratio = 4.35, 95% confidence interval = 1.35-14.0). Therefore, the results of this exploratory study indicated that an eosinophil proportion of ≥ 2.5% at the start of EV treatment may be a candidate biomarker for the occurrence of AEs of any grade."
Adverse events • Biomarker • Journal • Retrospective data • Diabetes • Metabolic Disorders • Oncology • Solid Tumor • Urothelial Cancer • CRP
|
|
Aya Naiki-Ito; Daiki Ishikawa; Hiroki Kubota; Keitaro Iida; Kunihiro Odagiri; Maria Aoki; Masakazu Gonda; Nobuhiko Shimizu; Noriyasu Kawai; Rika Banno; Ryosuke Ando; Takahiro Yasui; Takashi Nagai; Taku Naiki; Toshiharu Morikawa; Toshiki Etani; Yoko Furukawa-Hibi; Yoshihiko Tasaki; Yoshihisa Mimura; Yosuke Sugiyama; Yukihiro Umemoto; Yusuke Noda
|